EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Effect of phenylbutazone administration on the enteroinsular axis in horses with insulin dysregulation

Kate L Kemp iD, Jazmine E Skinner, François-René Bertin iD

Journal of Veterinary Internal Medicine · 2025

DOI: 10.1111/jvim.17256 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, 2025. Verfasst von Kate L Kemp und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Veterinary Science, The University of Queensland, 5391 Warrego Hwy, Gatton, Queensland, 4343, Australia. Hauptthemen laut MEDLINE: Phenylbutazone, Horse Diseases, Cross-Over Studies, Insulin. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Morris Animal Foundation, The University of Queensland Graduate School Research Training Program (RTP) Scholarship and Destination Australia Scholarship: Awarded to Kate L. Kemp.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Phenylbutazone is prescribed for laminitis-associated pain and decreases glucose and insulin responses to an oral glucose test (OGT) in horses with insulin dysregulation (ID). Hypothesis/Objectives Investigate the effect of phenylbutazone administration on the enteroinsular axis in horses. Animals Sixteen horses, including 7 with ID.

Methods

Randomized cross-over study design, with horses assigned to treatment with phenylbutazone (4.4 mg/kg IV q24h) or placebo (5 mL 0.9% saline). On Day 9 of treatment, an OGT was conducted, followed by a 10-day washout period, administration of the alternative treatment, and repetition of the OGT. Glucose-dependent insulinotropic polypeptide (GIP), and active glucagon-like peptide 1 and 2 (aGLP-1 and GLP-2) concentrations were determined by ELISA. The effects of ID status and treatment on peptide concentrations were assessed using t tests and analyses of variance.

Results

Horses with ID had significantly higher maximum GIP concentrations (Cmax) than controls (median, 279.1; interquartile range [IQR], 117.5-319.4 pg/mL vs median, 90.12; IQR, 74.62-116.5 pg/mL; P = .01), but no significant effect of ID was detected on aGLP-1 and GLP-2 concentrations. In horses with ID, phenylbutazone treatment significantly decreased GIP Cmax compared with placebo (168.1 ± 59.26 pg/mL vs 242.8 ± 121.8 pg/mL; P = .04), but no significant effect of phenylbutazone was detected on aGLP-1 and GLP-2 concentrations. Conclusion and Clinical Importance Glucose-dependent insulinotropic polypeptide, aGLP-1 and GLP-2 do not mediate the decrease in glucose and insulin concentrations observed after phenylbutazone administration. Only GIP was repeatedly associated with ID status, calling into question the role of the enteroinsular axis in ID.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhenylbutazoneHorse DiseasesCross-Over StudiesInsulinAnimalsHorsesMaleFemaleGlucose Tolerance TestGastric Inhibitory PolypeptideAnti-Inflammatory Agents, Non-SteroidalGlucagon-Like Peptide 1Blood Glucose

Stichwörter der Autor:innen

endocrinologyequine metabolic syndromehyperinsulinemialaminitisnon‐steroidal anti‐inflammatory drugsobesityoral glucose test

Substanzen

PhenylbutazoneInsulinGastric Inhibitory PolypeptideAnti-Inflammatory Agents, Non-SteroidalGlucagon-Like Peptide 1Blood Glucose

Autor:innen und Institutionen

  • School of Veterinary Science, The University of Queensland, 5391 Warrego Hwy, Gatton, Queensland, 4343, Australia.
  • School of Agriculture and Environmental Science, University of Southern Queensland, 487 - 35 West St, Darling Heights, Queensland, 4350, Australia.
  • College of Veterinary Medicine, Department of Veterinary Clinical Sciences, Purdue University, 625 Harrison St, West-Lafayette, Indiana, 47909, USA.

ORCID-Profile: Kate L Kemp, François-René Bertin

Förderung

  • Morris Animal Foundation
  • The University of Queensland Graduate School Research Training Program (RTP) Scholarship and Destination Australia Scholarship: Awarded to Kate L. Kemp

Zitieren

APA

Kemp, K. L., Skinner, J. E., & Bertin, F. R. (2025). Effect of phenylbutazone administration on the enteroinsular axis in horses with insulin dysregulation. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.17256

Vancouver

Kemp KL, Skinner JE, Bertin FR. Effect of phenylbutazone administration on the enteroinsular axis in horses with insulin dysregulation. Journal of Veterinary Internal Medicine. 2025. doi:10.1111/jvim.17256

BibTeX
@article{Kemp2025,
  author = {Kemp, Kate L and Skinner, Jazmine E and Bertin, François-René},
  title = {Effect of phenylbutazone administration on the enteroinsular axis in horses with insulin dysregulation},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2025},
  doi = {10.1111/jvim.17256}
}
Kostenlos starten →